Table I.
Baseline characteristics (n=143).
| Characteristics | No. or median value (range) |
|---|---|
| Age (years) | 71 (45–89) |
| Gender, male/female | 114/29 |
| Causes of liver disease | |
| Hepatitis B/C/non-B, non-C/B+C | 22/85/32/4 |
| Child-Pugh class, A/B | 102/41 |
| ECOG PS 0/1/2 | 119/19/5 |
| Tumor burden, <50/≥50% | 129/14 |
| Portal vein invasion, present/absent | 31/112 |
| Extrahepatic metastases, present/absent | 63/80 |
| AST (IU/l) | 52 (17–791) |
| ALT (IU/l) | 34 (7–380) |
| ALP (IU/l) | 405 (162–4535) |
| Total bilirubin (mg/dl) | 0.8 (0.3–2.5) |
| Serum albumin (g/dl) | 3.4 (1.7–4.8) |
| Prothrombin time (%) | 79 (48–116) |
| Platelet count (×104/mm3) | 11.5 (3.4–29.5) |
| AFP (ng/ml) | 139.1 (1.8–688,400) |
| DCP (mAU/ml)a | 1,341 (10–421,210) |
| Initial dose of sorafenib (mg/day), 800/400/200 | 35/106/2 |
a
Missing data, n=3. ECOG PS, Eastern Cooperative Oncology Group PERFORMANCE STATUS; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; AFP, α-fetoprotein; DCP, des-γ-carboxy prothrombin.